227. Osler disease
[
38 clinical trials,
44 drugs（DrugBank:
18 drugs),
12 target genes / 106 target pathways ]
Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler Weber Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04113187 | December 2019 | 14 October 2019 | Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Hereditary Hemorrhagic Telangiectasia;Osler Weber Rendu Disease | Drug: Propranolol treatment;Drug: Placebo | University Hospital, Bordeaux | AMRO-HHT-France - Association Maladie de Rendu-Osler | Not recruiting | 18 Years | N/A | All | 38 | Phase 3 | France |
| 2 | NCT04139018 | October 20, 2019 | 4 November 2019 | Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia | Efficacy of a Timolol Gel in the Care for Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia: A Double-Blinded, Randomized Controlled Trial | Hereditary Hemorrhagic Telangiectasia | Drug: Timolol Gel;Drug: Placebo Gel | Washington University School of Medicine | Institute of Clinical and Translational Sciences (ICTS) | Recruiting | 20 Years | N/A | All | 30 | Phase 2 | United States |
| 3 | NCT03910244 | October 2019 | 26 August 2019 | Pomalidomide for the Treatment of Bleeding in HHT | Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia | Telangiectasia, Hereditary Hemorrhagic | Drug: Pomalidomide Oral Product;Drug: Placebo oral capsule | The Cleveland Clinic | RTI International | Not recruiting | 18 Years | 99 Years | All | 159 | Phase 2 | |
| 4 | NCT03850730 | September 2019 | 4 March 2019 | Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia | An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Pazopanib | Cure HHT | University of North Carolina | Not recruiting | 18 Years | 75 Years | All | 30 | Phase 1/Phase 2 | |
| 5 | NCT03850964 | September 2019 | 4 March 2019 | Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia | Randomized Double Blind Study to Evaluate the Effect of Low Dose Pazopanib on Bleeding Due to Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed;Anemia | Drug: Pazopanib;Drug: Placebo oral capsule | Cure HHT | Not recruiting | 18 Years | 75 Years | All | 45 | Phase 2/Phase 3 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03397004 | September 12, 2018 | 21 January 2019 | Doxycycline for Hereditary Hemorrhagic Telangiectasia | Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Doxycycline Hyclate;Drug: Placebo | St. Michael's Hospital, Toronto | Barrow Neurological Institute;Duke University;Feinstein Institute for Medical Research;University of Pittsburgh;Sunnybrook Health Sciences Centre | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Canada |
| 7 | NCT03981562 | July 16, 2018 | 24 June 2019 | Vitamin D and Hereditary Haemorrhagic Telangiectasia | Vitamin D Supplementation and Reduction of Severity and Frequency of Epistaxis in Hereditary Haemorrhagic Telangiectasia | Hereditary Haemorrhagic Telangiectasia | Drug: Vit D;Drug: Placebo Oral Tablet | St. Paul's Hospital, Canada | Recruiting | 19 Years | N/A | All | 60 | Phase 2 | Canada | |
| 8 | NCT03572556 | June 28, 2018 | 10 December 2018 | Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) | Prospective Descriptive Study of the Angiogenic T Cell Population in Subjects With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia | Biological: Blood samples;Other: Epistaxis charts | Centre Hospitalier Universitaire Dijon | Recruiting | 18 Years | N/A | All | 50 | Phase 1 | France | |
| 9 | EUCTR2017-003272-31-NL | 18/05/2018 | 5 June 2018 | Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasia | Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia - Itraconazole for epistaxis in HHT patients | Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease MedDRA version: 20.0 Level: LLT Classification code 10031132 Term: Osler-Weber-Rendu disease System Organ Class: 100000004850 MedDRA version: 20.0 Level: LLT Classification code 10038554 Term: Rendu-Osler-Weber syndrome System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Sporanox Product Name: Itraconazole Pharmaceutical Form: Capsule | St. Antonius Ziekenhuis | Authorised | Female: yes Male: yes | 25 | Phase 2 | Netherlands | |||
| 10 | NCT02963129 | June 2017 | 21 November 2016 | Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT | Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis. | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Mupirocin;Other: Placebo | Hospital Italiano de Buenos Aires | Not recruiting | 18 Years | N/A | Both | 40 | Phase 3 | Argentina | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2016-003982-24-ES | 16/03/2017 | 28 February 2019 | Study to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeks | A phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of hereditary hemorrhagic telangiectasia, during 4 weeks | Hereditary hemorrhagic telangiectasia MedDRA version: 19.0 Level: LLT Classification code 10020023 Term: HHT System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Dicynone CAS Number: 2624444 Current Sponsor code: Etamsylate Other descriptive name: ETAMSYLATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 125- | Asociación HHT España | Not Recruiting | Female: yes Male: yes | 12 | Phase 2;Phase 4 | Spain | |||
| 12 | NCT02874326 | October 2016 | 11 June 2018 | Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber | An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding | Hereditary Hemorrhagic Telangiectasia;Gastrointestinal Hemorrhage;Anemia | Drug: Octreotide LAR | Radboud University | St. Antonius Hospital | Not recruiting | 18 Years | N/A | All | 15 | Phase 2 | Netherlands |
| 13 | EUCTR2016-001340-19-NL | 21/07/2016 | 8 August 2016 | The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease. | An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW | Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Sandostatin LAR 20 mg Product Name: Sandostatin LAR Product Code: RVG 18236 Pharmaceutical Form: Powder and solution for solution for injection | Radboud University Medical Center | Authorised | Female: yes Male: yes | Phase 2 | Netherlands | ||||
| 14 | NCT02638012 | December 2015 | 24 June 2019 | Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) | Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT);Epistaxis | Drug: Floseal;Other: Packing | St. Michael's Hospital, Toronto | The Ottawa Hospital | Recruiting | 18 Years | N/A | All | 10 | N/A | Canada |
| 15 | NCT02484716 | June 2015 | 12 February 2018 | Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) | Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo | Hemorrhagic Hereditary Telangiectasia (HHT) | Drug: Timolol nasal spray;Drug: Placebo nasal spray | Hospices Civils de Lyon | Not recruiting | 18 Years | N/A | All | 58 | Phase 2 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT02287558 | January 27, 2015 | 20 August 2018 | Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study | A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia | Hereditary Hemorrhagic Telangiectasia;Idiopathic Vascular Ectasia | Drug: Pomalidomide | The Cleveland Clinic | Recruiting | 18 Years | N/A | All | 9 | Phase 1 | United States | |
| 17 | NCT02157987 | December 2014 | 19 February 2015 | Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose | Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose | Telangiectasia, Hereditary Hemorrhagic | Drug: bevacuzimab spray | University Hospital, Caen | Recruiting | 18 Years | 70 Years | Both | 30 | Phase 1/Phase 2 | France | |
| 18 | NCT02389959 | August 2014 | 16 December 2017 | Intranasal Bevacizumab for HHT-Related Epistaxis | Intranasal Bevacizumab for HHT-Related Epistaxis | HHT;Hereditary Hemorrhagic Telangiectasia;Epistaxis;Nose Bleeds;Nasal Bleeding | Drug: Bevacizumab;Drug: Placebo (Saline) | Stanford University | Recruiting | 18 Years | N/A | All | 40 | Phase 4 | United States | |
| 19 | NCT02106520 | April 2014 | 7 December 2015 | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Bevacizumab;Drug: placebo | Hospices Civils de Lyon | Not recruiting | 18 Years | N/A | Both | 80 | Phase 2/Phase 3 | France | |
| 20 | EUCTR2013-004204-19-FR | 26/02/2014 | 7 December 2015 | Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler | Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler - ALEGORI | Rendu-Osler disease MedDRA version: 18.0 Level: LLT Classification code 10031132 Term: Osler-Weber-Rendu disease System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Avastin Product Name: Avastin Pharmaceutical Form: Solution for infusion INN or Proposed INN: BEVACIZUMAB CAS Number: 216974-75-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Nasal use | Hospices Civils de Lyon | Not Recruiting | Female: yes Male: yes | France | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT01908543 | July 2013 | 22 October 2019 | Iron Deficiency and Hereditary Haemorrhagic Telangiectasia | Iron Deficiency and Hereditary Haemorrhagic Telangiectasia | Hereditary Haemorrhagic Telangiectasia | Drug: Ferrous sulphate 200mg oral tablet | Imperial College London | Not recruiting | 18 Years | 80 Years | All | 3 | N/A | United Kingdom | |
| 22 | NCT01752049 | May 2013 | 30 September 2019 | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Hereditary Hemorrhagic Telangiectasia | Drug: Topical timolol maleate;Drug: placebo saline drops | St. Michael's Hospital, Toronto | University of California, San Francisco;The Hospital for Sick Children;University of Toronto;Sunnybrook Health Sciences Centre;Ryerson University;National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 18 Years | N/A | All | 5 | N/A | Canada |
| 23 | NCT01485224 | November 2011 | 16 December 2017 | Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia | Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis | Drug: Thalidomide | IRCCS Policlinico S. Matteo | Not recruiting | 18 Years | N/A | All | 31 | Phase 2 | Italy | |
| 24 | NCT01507480 | October 2011 | 19 February 2015 | The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia | The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia. | Hemorrhagic Hereditary Telangiectasia | Drug: Bevacizumab | Hospices Civils de Lyon | Not recruiting | 18 Years | N/A | Both | 42 | Phase 1 | France | |
| 25 | NCT01408030 | August 2011 | 22 October 2018 | North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | North American Study of Epistaxis in HHT (NOSE) | Telangiectasia, Hereditary Hemorrhagic;Epistaxis | Drug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic Acid | James Gossage | HHT Foundation International | Not recruiting | 18 Years | N/A | All | 123 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT01406639 | July 2011 | 19 February 2015 | Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT);Nosebleeds | Drug: Ranibizumab | University of California, San Diego | Genentech, Inc. | Not recruiting | 18 Years | N/A | Both | 0 | Phase 1 | United States |
| 27 | NCT01408732 | February 2011 | 11 November 2019 | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia | Epistaxis;Hereditary Hemorrhagic Telangiectasia | Drug: Sclerotherapy;Other: Standard Treatment | University of Minnesota | American Rhinologic Society | Not recruiting | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | United States |
| 28 | EUCTR2009-018049-19-AT | 13/12/2010 | 12 May 2014 | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT | epistaxis | Trade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung Pharmaceutical Form: Solution for injection INN or Proposed INN: BEVACIZUMAB CAS Number: 216974-75-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: -10 Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Pharmaceutical Form: Solution for injection CAS Number: 7647-14-5 Other descriptive name: SODIUM CHLORIDE Concentration unit: ml millilitre(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intranasal use (Noncurrent) | Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten | Not Recruiting | Female: yes Male: yes | 30 | Austria | ||||
| 29 | NCT01402531 | July 2010 | 19 February 2015 | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Submucosal Bevacizumab | University of California, San Diego | Recruiting | 18 Years | N/A | Both | 30 | Phase 2 | United States | |
| 30 | NCT01397695 | June 2009 | 19 February 2015 | Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: Bevacizumab | University of California, San Diego | Recruiting | 18 Years | N/A | Both | 50 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2008-006755-44-FR | 15/01/2009 | 19 March 2012 | METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE | METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II - METAFORE | Maladie de Rendu-Osler MedDRA version: 9.1 Level: LLT Classification code 10031132 Term: Osler-Weber-Rendu disease | Trade Name: AVASTIN Product Name: AVASTIN Pharmaceutical Form: Solution for infusion INN or Proposed INN: BEVACIZUMAB Other descriptive name: SUB16402MIG Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- | HOSPICES CIVILS DE LYON | Authorised | Female: yes Male: yes | Phase 2 | France | ||||
| 32 | EUCTR2010-020545-26-IT | 09/12/2008 | 19 March 2012 | BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND | BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND | HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) MedDRA version: 9.1 Level: SOC Classification code 10005329 | Trade Name: AVASTIN Pharmaceutical Form: Solution for infusion INN or Proposed INN: Bevacizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Trade Name: AVASTIN Pharmaceutical Form: Solution for infusion INN or Proposed INN: Bevacizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Trade Name: AVASTIN Pharmaceutical Form: Solution for infusion INN or Proposed INN: Bevacizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- | AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | Authorised | Female: yes Male: yes | Italy | |||||
| 33 | NCT00588146 | January 2007 | 19 October 2017 | Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia | Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia | Anemia;Liver Disease;Hypoxemia | Drug: Pegylated Interferon Alpha2b;Other: Standard care | Mayo Clinic | Augusta University;St. Michael's Hospital, Toronto;Schering-Plough | Not recruiting | 18 Years | 70 Years | All | 10 | Phase 2 | United States |
| 34 | NCT00389935 | October 2006 | 19 February 2015 | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena | Drug: Thalidomide | Northport Veterans Affairs Medical Center | Georgia Regents University;University of Massachusetts, Worcester | Not recruiting | 18 Years | N/A | Both | 14 | Phase 2 | United States |
| 35 | NCT00375622 | February 2005 | 19 February 2015 | Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial | Hereditary Hemorrhagic Telangiectasia | Drug: Tamoxifen | Rabin Medical Center | Not recruiting | 18 Years | N/A | Both | 60 | Phase 2 | Israel | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01031992 | March 2002 | 19 February 2015 | Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia | Drug: Tranexamic acid first, than placebo;Drug: First placebo, than Tranexamic acid. | University Hospital, Saarland | Pharmacia GmbH, Erlangen, Germany;Baxter Healthcare Corporation | Not recruiting | 18 Years | N/A | Both | 23 | Phase 3 | Germany |
| 37 | NCT00004654 | January 1996 | 19 February 2015 | Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia | Hereditary Hemorrhagic Telangiectasia | Drug: soy protein isolate | National Center for Research Resources (NCRR) | Yale University | Not recruiting | 15 Years | N/A | Both | 60 | Phase 3 | ||
| 38 | NCT00004327 | January 1995 | 19 February 2015 | Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia | Hereditary Hemorrhagic Telangiectasia;Ectasia | Drug: octreotide | National Center for Research Resources (NCRR) | Yale University | Not recruiting | N/A | N/A | Both | 8 | Phase 2 |